Browsing by Subject "BLOCKADE"
Now showing items 1-1 of 1
-
(Journal of Clinical Oncology, 2019-04-20)PURPOSE CheckMate 568 is an open-label phase II trial that evaluated the efficacy and safety of nivolumab plus low-dose ipilimumab as first-line treatment of advanced/metastatic non-small-cell lung cancer (NSCLC). We ...